Immunotherapy Approaches for Malignant Glioma From 2007 to 2009
- 23 April 2010
- journal article
- review article
- Published by Springer Science and Business Media LLC in Current Neurology and Neuroscience Reports
- Vol. 10 (4), 259-266
- https://doi.org/10.1007/s11910-010-0111-9
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Two phase II trials of temozolomide with interferon-α2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiformeBritish Journal of Cancer, 2009
- Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastomaNature Medicine, 2008
- A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomasJournal of Neuro-Oncology, 2008
- Cytomegalovirus Immunity after Vaccination with Autologous Glioblastoma LysateNew England Journal of Medicine, 2008
- Postoperative Adjuvant Dendritic Cell–Based Immunotherapy in Patients with Relapsed Glioblastoma MultiformeClinical Cancer Research, 2008
- Immunotherapy of malignant brain tumorsImmunological Reviews, 2008
- Cancer Regression in Patients After Transfer of Genetically Engineered LymphocytesScience, 2006
- Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trialThe Lancet Oncology, 2006
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapseBritish Journal of Cancer, 2000